Your browser is no longer supported. Please, upgrade your browser.
Settings
ACAD ACADIA Pharmaceuticals Inc. daily Stock Chart
ACAD [NASD]
ACADIA Pharmaceuticals Inc.
Index- P/E- EPS (ttm)-2.46 Insider Own0.10% Shs Outstand120.85M Perf Week-4.95%
Market Cap3.50B Forward P/E- EPS next Y-1.74 Insider Trans-49.47% Shs Float120.45M Perf Month7.97%
Income-299.20M PEG- EPS next Q-0.58 Inst Own99.90% Short Float7.22% Perf Quarter-21.63%
Sales93.30M P/S37.54 EPS this Y-43.30% Inst Trans-1.78% Short Ratio5.81 Perf Half Y3.54%
Book/sh3.08 P/B9.41 EPS next Y27.80% ROA-61.90% Target Price49.78 Perf Year11.42%
Cash/sh3.03 P/C9.55 EPS next 5Y38.30% ROE-67.70% 52W Range24.82 - 41.20 Perf YTD0.49%
Dividend- P/FCF- EPS past 5Y-40.00% ROI-52.90% 52W High-29.66% Beta3.81
Dividend %- Quick Ratio11.00 Sales past 5Y53.00% Gross Margin91.10% 52W Low16.76% ATR1.24
Employees425 Current Ratio11.10 Sales Q/Q571.70% Oper. Margin- RSI (14)42.82 Volatility3.82% 3.92%
OptionableYes Debt/Eq0.00 EPS Q/Q12.60% Profit Margin- Rel Volume1.10 Prev Close28.97
ShortableYes LT Debt/Eq0.00 EarningsNov 07 AMC Payout- Avg Volume1.50M Price28.98
Recom2.00 SMA200.05% SMA50-9.66% SMA200-9.54% Volume1,640,553 Change0.03%
Oct-06-17Resumed Goldman Neutral
Nov-11-16Initiated Goldman Neutral
Nov-08-16Upgrade BofA/Merrill Neutral → Buy
Oct-19-16Resumed ROTH Capital Neutral
Oct-04-16Initiated Leerink Partners Mkt Perform $34
Jun-22-16Downgrade BofA/Merrill Buy → Neutral
May-03-16Downgrade Leerink Partners Outperform → Mkt Perform
Mar-30-16Reiterated Piper Jaffray Overweight $39 → $44
Feb-08-16Initiated BofA/Merrill Buy $40
Jan-22-16Upgrade Piper Jaffray Neutral → Overweight
Aug-27-15Upgrade Piper Jaffray Neutral → Overweight $48
Aug-07-15Reiterated Needham Buy $38 → $49
Aug-07-15Downgrade Piper Jaffray Overweight → Neutral
Apr-16-15Initiated Leerink Partners Outperform $48
Mar-12-15Reiterated Needham Buy $40 → $38
Feb-24-15Initiated H.C. Wainwright Buy $50
Feb-06-15Resumed ROTH Capital Buy $42
Dec-22-14Reiterated Needham Buy $26 → $40
Aug-07-13Reiterated Needham Buy $16 → $26
Aug-07-13Reiterated Ladenburg Thalmann Buy $15 → $24
Dec-14-17 10:09AM  Shire's New Formulation of Oncaspar Gets Approval in Europe Zacks
Dec-13-17 09:40AM  Glaxo's Nucala Label Expansion Application Gets FDA Approval Zacks
09:24AM  Proteostasis Stock Surges on Positive Data From CF Studies Zacks
09:00AM  ACADIA Pharmaceuticals Announces Appointment of Damien McDevitt, Ph.D., as Senior Vice President, Corporate Development Business Wire
Dec-11-17 07:05PM  Cramer Remix: Heres the most volatile stock Ive ever co... CNBC Videos
06:59PM  Cramer Remix: Acadia is the most volatile stock Ive ever covered and its worth speculating on CNBC
02:12PM  Lilly Reports Mixed Results from Late-Stage Cyramza Study Zacks
Dec-08-17 01:59PM  5 Cheap Biotech Stocks to Snag on the Bounce InvestorPlace
08:05AM  See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc. Markit
Dec-06-17 08:10AM  Todays Research Reports on Trending Tickers: ACADIA Pharmaceuticals and Moleculin Biotech ACCESSWIRE
Dec-04-17 06:04AM  Here's How Acadia Pharmaceuticals Crushed It in 2017 Motley Fool
Nov-30-17 04:55PM  Medicines Company to Sell Infectious Disease Unit to Melinta Zacks
08:10AM  Report: Developing Opportunities within Procter & Gamble, ACADIA Pharmaceuticals, Cree, Umpqua, Westrock, and Globus Medical Future Expectations, Projections Moving into 2018 GlobeNewswire
Nov-29-17 08:04AM  See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc. Markit
Nov-28-17 08:01AM  See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc. Markit
Nov-27-17 10:06AM  Spectrum Doubles in 3 Months: What's Driving the Rally? Zacks
Nov-21-17 09:00AM  ACADIA Pharmaceuticals to Present at the 29th Annual Piper Jaffray Healthcare Conference on November 28, 2017 Business Wire
08:47AM  This $12 Billion Hedge Fund Is Switching to Synergy Pharmaceuticals, Away from ACADIA Investopedia
Nov-17-17 02:43PM  Why Biotech Sage Therapeutics Is Overvalued Investopedia
Nov-15-17 08:02AM  See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc. Markit
Nov-14-17 08:02AM  See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc. Markit
Nov-13-17 04:46PM  Edited Transcript of ACAD earnings conference call or presentation 7-Nov-17 10:00pm GMT Thomson Reuters StreetEvents
10:56AM  ACADIA Pharmaceuticals Has This Top Analyst Even More Positive on PDP Drug Nuplazids Opportunity SmarterAnalyst
Nov-11-17 07:21AM  Better Buy: Acadia Pharmaceuticals vs. Biogen Motley Fool
Nov-09-17 08:20AM  Todays Research Reports on Trending Tickers: ACADIA Pharmaceuticals and Spark Therapeutics ACCESSWIRE
06:00AM  Why Biotech Acadia May Be Oversold Investopedia
Nov-08-17 12:26PM  H.C. Wainwright: Acadia Is More Than A One-Trick Pony Benzinga -9.40%
Nov-07-17 07:38PM  Is It Time To Buy ACADIA Pharmaceuticals Inc (ACAD)? Simply Wall St.
05:28PM  Nektar, Acadia Pop On Street-Crushing Quarters, But Tesaro Dips Investor's Business Daily
04:19PM  ACADIA Pharmaceuticals Inc. (ACAD) 3Q:17 Net Sales Grew to $35.6 Million SmarterAnalyst
04:13PM  Acadia reports 3Q loss Associated Press
04:05PM  ACADIA Pharmaceuticals Reports Third Quarter 2017 Financial Results Business Wire
Nov-06-17 10:59AM  ETFs with exposure to ACADIA Pharmaceuticals, Inc. : November 6, 2017 Capital Cube -9.21%
Nov-03-17 02:41PM  ACADIA Pharmaceuticals Inc. (ACAD) Announces Presentation of Data Showing Greater Benefit in Patients with Severe Psychosis SmarterAnalyst
01:30PM  ACADIA Pharmaceuticals Presents Data from the Phase II Study of Pimavanserin in Alzheimers Disease Psychosis at the Clinical Trials on Alzheimers Disease (CTAD) 2017 Meeting Business Wire
03:00AM  Acadia Pharmaceuticals Scores Relative Strength Rating Upgrade; Hits Key Threshold Investor's Business Daily
Oct-31-17 12:12PM  Is ACADIA (ACAD) Likely to Beat Earnings Estimates in Q3? Zacks
09:00AM  ACADIA Pharmaceuticals to Announce Third Quarter 2017 Financial Results on November 7, 2017 Business Wire
07:45AM  Consolidated Research: 2018 Summary Expectations for Columbia Property Trust, Dr Pepper Snapple, Immune Pharmaceuticals, Air Products and Chemicals, Box, and ACADIA Pharma Fundamental Analysis, Key Performance Indications GlobeNewswire
Oct-30-17 10:11AM  Edited Transcript of ACAD earnings conference call or presentation 7-Nov-16 10:00pm GMT Thomson Reuters StreetEvents
09:56AM  Edited Transcript of ACAD earnings conference call or presentation 5-May-16 9:00pm GMT Thomson Reuters StreetEvents
Oct-27-17 10:40AM  ETFs with exposure to ACADIA Pharmaceuticals, Inc. : October 27, 2017 Capital Cube
Oct-26-17 11:00AM  ACADIA Pharmaceuticals, Inc. Value Analysis (NASDAQ:ACAD) : October 26, 2017 Capital Cube
Oct-25-17 08:15AM  ACADIA Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ACAD-US : October 25, 2017 Capital Cube
Oct-18-17 08:02AM  See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc. Markit
Oct-16-17 08:07AM  See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc. Markit
Oct-13-17 03:01PM  Valeant Reports Positive Results on Psoriasis Drug Siliq Zacks
09:02AM  Lilly's Verzenio Gets Priority Review in First-Line Setting Zacks
08:07AM  See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc. Markit
Oct-12-17 06:56PM  Here's Why Intercept (ICPT) Stock Lost 37% So Far in 2017 Zacks
08:16AM  See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc. Markit
Oct-11-17 03:34PM  Allergan's Uterine Fibroids Candidate's NDA Accepted by FDA Zacks
11:09AM  ETFs with exposure to ACADIA Pharmaceuticals, Inc. : October 11, 2017 Capital Cube
Oct-10-17 04:50PM  Mallinckrodt to Begin Sarcoidosis Study on Acthar Gel Zacks
09:34AM  Why Should You Invest in Novo Nordisk (NVO) Stock Right Now Zacks
08:03AM  See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc. Markit
Oct-09-17 09:25AM  Emergent BioSolutions Acquires Sanofi's Smallpox Vaccine Unit Zacks
08:03AM  See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc. Markit
Oct-06-17 08:40AM  Pros And Cons Of All The News Out Of Acadia Pharma This Week Benzinga
08:04AM  See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc. Markit
Oct-05-17 04:47PM  This Biotech Rockets Then Dips After FDA Breakthrough Win Investor's Business Daily
02:20PM  Acadia's FDA Breakthrough Designation For Pimavanserin Draws Mixed Response Benzinga
11:57AM  ACADIA's Antipsychotic Drug Gets Breakthrough Therapy Status Zacks
10:52AM  Ligand (LGND) Signs Deal to Acquire Crystal Bioscience Zacks
10:07AM  Acadia Pharma Could Rise Another 25 Percent to $50 Investopedia
09:01AM  Acadia Pharma Stock Rockets On Drug Breakthrough Nod Investor's Business Daily
08:03AM  See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc. Markit
08:00AM  Today's Research Reports on Trending Tickers: ACADIA Pharmaceuticals and ImmunoGen ACCESSWIRE
Oct-04-17 06:49PM  Acadia shares rise on FDA dementia drug designation MarketWatch
06:43PM  2 Stocks Move in After-Hours Trading GuruFocus.com
04:05PM  ACADIA Pharmaceuticals Initiates Phase III Study of Pimavanserin in Dementia-Related Psychosis Business Wire
Sep-26-17 05:07PM  Allergan Authorizes New $2B Share Buyback Plan, Stock Up Zacks
11:13AM  Biotech Acadia Could Rise 30 Percent To $50 Investopedia
Sep-25-17 08:03AM  See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc. Markit
Sep-22-17 08:01AM  See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc. Markit
Sep-21-17 03:00PM  Billionaires Are Gobbling Up This Beaten-Down Biotech Stock: Should You? Motley Fool
Sep-19-17 03:12PM  Supernus Drops SPN-810's Lower Dose Test in Phase III Trials Zacks
09:00AM  ACADIA Pharmaceuticals to Present at the Ladenburg Thalmann 2017 Healthcare Conference on September 26, 2017 Business Wire
08:03AM  See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc. Markit
Sep-18-17 08:02AM  See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc. Markit
Sep-15-17 08:01AM  See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc. Markit
Sep-14-17 05:50PM  GTx's (GTXI) Enobosarm Positive in Phase II, Shares Down Zacks
11:05AM  Alexion (ALXN) Reports Interim Results for Soliris Study Zacks
Sep-13-17 11:29AM  Perrigo's Stock Up, Starboard's CEO Calls it a Key Pick Zacks
Sep-12-17 11:42AM  Marinus Stock Surges on Successful Phase II Epilepsy Study Zacks
08:02AM  See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc. Markit
Sep-11-17 08:00AM  Today's Research Reports on Trending Tickers: ACADIA Pharmaceuticals and Clovis Oncology ACCESSWIRE
Sep-08-17 05:06PM  Nuplazid for Long-Term Care: Revenue Driver for Acadia? Market Realist
03:36PM  Nuplazid Sees Increasing Physician Intent to Prescribe in 2017 Market Realist
02:01PM  Nuplazid Expected to Become a Leading Central Nervous System Drug Market Realist
Sep-07-17 01:24PM  BioMarin Presents Interim Data on BMN 250 from Phase I/II Zacks
11:55AM  ETFs with exposure to ACADIA Pharmaceuticals, Inc. : September 7, 2017 Capital Cube
10:32AM  Merck (MRK) Opts for Buying German Immuno-Oncology Biotech Zacks
09:08AM  Acadia Could Report Robust Revenue Growth in 2017 Market Realist
07:37AM  What Analysts Recommend for Acadia Pharmaceuticals in September Market Realist
Sep-05-17 11:47AM  ACADIA Pharmaceuticals, Inc. :ACAD-US: Earnings Analysis: Q2, 2017 By the Numbers : September 5, 2017 Capital Cube
Aug-30-17 11:06AM  FDA's Refusal-to-File Letter for Inbrija Pushes Acorda Down Zacks
03:00AM  Stocks To Watch: Acadia Pharmaceuticals Sees RS Rating Jump To 83 Investor's Business Daily
Aug-29-17 08:04AM  See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc. Markit
Aug-28-17 07:02PM  Minerva-J&J's Amendment of MIN-202 Contract Wins EU Approval Zacks
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. Its lead product candidate, NUPLAZID, has completed the Phase III pivotal trials for the treatment of Parkinson's disease psychosis and the Phase II trial for the treatment of schizophrenia, as well as is in Phase II study for the treatment of Alzheimer's disease psychosis. The company has a collaboration with Allergan, Inc. for the development of product candidates related to chronic pain. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BAKER BROS. ADVISORS LPDirectorNov 27Option Exercise1.3839,37854,342491,918Nov 29 04:00 PM
BAKER BROS. ADVISORS LPDirectorOct 13Option Exercise1.381,426,5901,968,69423,763,865Oct 16 05:15 PM
Baity GlennEVP AND GCOct 05Option Exercise1.9128,50054,330107,156Oct 06 06:20 PM
Baity GlennEVP AND GCOct 05Sale40.9137,5001,534,04369,656Oct 06 06:20 PM
Baity GlennEVP AND GCOct 04Option Exercise1.8511,00020,34078,656Oct 06 06:20 PM
Baity GlennEVP AND GCAug 30Option Exercise1.6216,50726,74194,163Sep 01 05:15 PM
Baity GlennEVP AND GCAug 30Sale34.8726,507924,31567,656Sep 01 05:15 PM
Baity GlennEVP AND GCAug 09Option Exercise1.6214,32223,13791,978Aug 11 05:38 PM
Baity GlennEVP AND GCAug 09Sale34.8814,322499,53477,656Aug 11 05:38 PM
Baity GlennEVP AND GCAug 04Option Exercise1.626,50010,53077,656Aug 08 06:29 PM
Baity GlennEVP AND GCJul 20Option Exercise1.6228,09745,517109,253Jul 21 05:25 PM
Baity GlennEVP AND GCJul 20Sale30.0038,0971,142,91071,156Jul 21 05:25 PM
Baity GlennEVP AND GCJun 22Option Exercise1.621,9033,08383,059Jun 26 05:35 PM
Baity GlennEVP AND GCJun 22Sale30.001,90357,09181,156Jun 26 05:35 PM
Baity GlennEVP AND GCMay 15Option Exercise1.6214,09322,83181,156May 17 05:42 PM
Moore Terrence OEVP, CHIEF COMMERCIAL OFFICERFeb 21Option Exercise34.457,856270,6399,527Feb 23 06:01 PM
Moore Terrence OEVP, CHIEF COMMERCIAL OFFICERFeb 21Sale39.657,856311,4901,671Feb 23 06:01 PM
Moore Terrence OEVP, CHIEF COMMERCIAL OFFICERFeb 16Option Exercise28.4466,7521,898,34868,423Feb 16 07:06 PM
Moore Terrence OEVP, CHIEF COMMERCIAL OFFICERFeb 16Sale39.8866,7522,662,1161,671Feb 16 07:06 PM
Moore Terrence OEVP, CHIEF COMMERCIAL OFFICERFeb 15Option Exercise19.611,70033,3373,371Feb 16 07:06 PM
Moore Terrence OEVP, CHIEF COMMERCIAL OFFICERFeb 15Sale39.651,70067,4051,671Feb 16 07:06 PM
Baity GlennEVP AND GCFeb 14Option Exercise6.7126,365176,83993,428Feb 16 07:05 PM
Moore Terrence OEVP, CHIEF COMMERCIAL OFFICERFeb 14Option Exercise19.6187,1281,708,58090,759Feb 16 07:06 PM
Moore Terrence OEVP, CHIEF COMMERCIAL OFFICERFeb 14Sale39.6989,0883,535,5731,671Feb 16 07:06 PM
Baity GlennEVP AND GCFeb 14Sale39.6626,3651,045,51767,063Feb 16 07:05 PM
Baity GlennEVP AND GCFeb 01Option Exercise1.5521,07832,67198,141Feb 03 06:50 PM
Baity GlennEVP AND GCFeb 01Sale35.1531,0781,092,38267,063Feb 03 06:50 PM
Baity GlennEVP AND GCDec 28Option Exercise1.625,5008,91077,063Dec 29 05:09 PM
Baity GlennEVP AND GCDec 27Option Exercise1.559,80015,19081,363Dec 29 05:09 PM
Baity GlennEVP AND GCDec 27Sale30.469,800298,47471,563Dec 29 05:09 PM
Baity GlennEVP AND GCDec 20Option Exercise1.5510,00015,50081,563Dec 21 07:03 PM
Baity GlennEVP AND GCDec 20Sale30.0010,000300,00171,563Dec 21 07:03 PM
Baity GlennEVP AND GCDec 19Option Exercise1.648,63514,16171,563Dec 21 07:03 PM